Co-expression of β-arrestin1 and NF-кB is associated with cancer progression and poor prognosis in lung adenocarcinoma

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 6551-6558

  Yu, Jianyu ^a,b   Wang, Liguang ^a   Zhang, Tiehong ^a   Shen, Hongchang ^a   Dong, Wei ^a   Ni, Yang ^a   Du, Jiajun ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b 230th Hospital of PLA   (China)

Author keywords

Lung adenocarcinoma; NF B; p65; Prognosis; arrestin1

Indexed keywords

BETA ARRESTIN 1; TRANSCRIPTION FACTOR RELA; BETA ARRESTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RETINA S ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; AGED; BIOSYNTHESIS; CANCER STAGING; CARCINOGENESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ARRESTINS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTION FACTOR RELA; TUMOR MARKERS, BIOLOGICAL;

EID: 84940435107     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3349-7     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90.
2. Buchanan FG, DuBois RN. Emerging roles of beta-arrestins. Cell Cycle. 2006;5:2060–3.
3. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell. 2005;123:833–47.
4. Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S, et al. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem. 2002;277:37693–701.
5. Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem. 2003;278:11648–53.
6. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A. 2007;104:12011–6.
7. Ma L, Pei G. Beta-arrestin signaling and regulation of transcription. J Cell Sci. 2007;120:213–8.
8. Parathath SR, Mainwaring LA, Fernandez LA, Guldal CG, Nahle Z, Kenney AM. Beta-arrestin-1 links mitogenic sonic hedgehog signaling to the cell cycle exit machinery in neural precursors. Cell Cycle. 2010;9:4013–24.
9. Yue R, Kang J, Zhao C, Hu W, Tang Y, Liu X, et al. Beta-arrestin1 regulates zebrafish hematopoiesis through binding to YY1 and relieving polycomb group repression. Cell. 2009;139:535–46.
10. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006;103:1492–7.
11. Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, et al. Beta-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene. 2012;31:282–92.
12. Zecchini V, Madhu B, Russell R, Pertega-Gomes N, Warren A, Gaude E, et al. Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO J. 2014;33:1365–82.
13. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. 2011;103:317–33.
14. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. Beta-arrestin inhibits NF-kappa B activity by means of its interaction with the NF-kappa B inhibitor I kappa B alpha. Proc Natl Acad Sci U S A. 2004;101:8603–7.
15. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6:203–8.
16. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The I kappa B-NF-kappa B signaling module: temporal control and selective gene activation. Science. 2002;298:1241–5.
17. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.
18. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.
19. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17–26.
20. Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology. 2010;78:181–8.
21. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A. 2001;98:10386–91.
22. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, et al. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:5501–7.
23. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.
24. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, et al. Wistuba, II: nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006;107:2637–46.
25. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature. 2006;441:431–6.
26. Karin M, Greten FR. Nf-kappab: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.
27. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
28. Hoeppner CZ, Cheng N, Ye RD. Identification of a nuclear localization sequence in beta-arrestin-1 and its functional implications. J Biol Chem. 2012;287:8932–43.
29. Yang M, He RL, Benovic JL, Ye RD. Beta-arrestin1 interacts with the G-protein subunits beta(1)gamma(2) and promotes beta(1)gamma(2)-dependent Akt signalling for NF-kappa B activation. Biochem J. 2009;417:287–96.
30. Yang M, Zhang H, Voyno-Yasenetskaya T, Ye RD. Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation. Mol Pharmacol. 2003;64:447–55.
31. Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosano L: Beta-arrestin 1 is required for endothelin-1-induced NF-kappaB activation in ovarian cancer cells. Life sciences 2014
32. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
33. Sobolesky PM, Moussa O. The role of beta-arrestins in cancer. Prog Mol Biol Transl Sci. 2013;118:395–411.
34. Rosano L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, et al. Beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling. Oncogene. 2013;32:5066–77.
35. Angileri FF, Aguennouz M, Conti A, La Torre D, Cardali S, Crupi R, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer. 2008;112:2258–66.
36. Li D, Beisswenger C, Herr C, Schmid RM, Gallo RL, Han G, et al. Expression of the antimicrobial peptide cathelicidin in myeloid cells is required for lung tumor growth. Oncogene. 2014;33:2709–16.
37. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res: MCR. 2008;6:364–71.
38. Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R. Nf-kappaB protein expression associates with (18)F-FDG pet tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer. 2014;83:189–96.
39. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, et al. Nuclear factor kappa B transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116:3276–84.
40. Yang S-H, Hsu C-H, Lee J-C, Tien Y-W, Kuo S-H, Cheng A-L. Nuclear expression of glioma-associated oncogene homo log 1 and nuclear factor-kappa B is associated with a poor prognosis of pancreatic cancer. Oncology. 2013;85:86–94.
41. Hatata T, Higaki K, Tatebe S, Shomori K, Ikeguchi M. Immunohistochemical study of nuclear factor-kappaB expression in esophageal squamous cell carcinoma: prognostic significance and sensitivity to treatment with 5-fu. Dis Esophagus: Off J Int Soc Dis Esophagus ISDE. 2012;25:716–22.
42. Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, et al. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res. 2004;24:1071–5.